A detailed history of Jane Street Group, LLC transactions in Scholar Rock Holding Corp stock. As of the latest transaction made, Jane Street Group, LLC holds 63,082 shares of SRRK stock, worth $2.34 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
63,082
Previous 155,788 59.51%
Holding current value
$2.34 Million
Previous $1.3 Million 61.06%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.63 - $9.71 $707,346 - $900,175
-92,706 Reduced 59.51%
63,082 $505,000
Q2 2024

Aug 14, 2024

SELL
$7.84 - $16.79 $694,075 - $1.49 Million
-88,530 Reduced 36.24%
155,788 $1.3 Million
Q1 2024

May 15, 2024

BUY
$13.2 - $17.76 $1.58 Million - $2.12 Million
119,363 Added 95.52%
244,318 $4.34 Million
Q4 2023

Feb 14, 2024

BUY
$6.52 - $20.32 $814,706 - $2.54 Million
124,955 New
124,955 $2.35 Million
Q1 2023

May 15, 2023

BUY
$7.36 - $12.72 $1.49 Million - $2.57 Million
201,942 Added 611.82%
234,949 $1.88 Million
Q4 2022

Feb 14, 2023

BUY
$7.02 - $9.76 $231,709 - $322,148
33,007 New
33,007 $298,000
Q2 2022

Aug 16, 2022

SELL
$4.66 - $13.96 $74,354 - $222,745
-15,956 Closed
0 $0
Q1 2022

May 17, 2022

BUY
$11.89 - $24.68 $189,716 - $393,794
15,956 New
15,956 $206,000
Q4 2021

Feb 15, 2022

SELL
$24.14 - $35.18 $244,972 - $357,006
-10,148 Closed
0 $0
Q3 2021

Nov 16, 2021

BUY
$27.38 - $42.21 $49,639 - $76,526
1,813 Added 21.75%
10,148 $335,000
Q2 2021

Aug 16, 2021

BUY
$26.34 - $46.62 $219,543 - $388,577
8,335 New
8,335 $241,000
Q1 2021

May 18, 2021

SELL
$45.96 - $68.02 $201,304 - $297,927
-4,380 Closed
0 $0
Q4 2020

Feb 17, 2021

BUY
$13.72 - $51.57 $60,093 - $225,876
4,380 New
4,380 $213,000

Others Institutions Holding SRRK

About Scholar Rock Holding Corp


  • Ticker SRRK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,640,600
  • Market Cap $1.91B
  • Description
  • Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clini...
More about SRRK
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.